This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Sitaxentan, Sitaxsentan, PF-1228305
Description: Sitaxsentan is a small molecule selective inhibitor of the endothelin A receptor. Endothelin is a small peptide hormone that is believed to play a critical role in the control of blood flow and cell growth.
Deal Structure: In June 2000, ICOS and Encysive formed a joint venture to develop Sitaxsentan. On January 30, 2003, ICOS elected to terminate the joint venture. Encysive reacquired all rightsto the program for a closing payment of $4M with additional payments of $4M and $2M due in2004.
On June 16, 2005, Encysive Pharmaceuticals announced plans to market Thelin directly in Europe.
In April 2008, Encysive became a wholly-owned subsidiary of Pfizer.
Pink Sheet Thelin Has Late July User Fee Date
Additional information available to subscribers only: